ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.344,88
0,30%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7346
0,00%
Bitcoin
84.714,01
1,04%
Brent Oil
71,775
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vistagen Therapeutics Inc (VTGN)

  7. Vistagen Therapeutics Inc (VTGN) Notícias

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VTGN
DataHoraFonteTítuloCódigoCompanhia
19/03/202509:30Business WireVistagen to Present at the 2025 Anxiety and Depression Association ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
06/03/202518:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
20/02/202510:30Business WireVistagen to Participate in the 45th Annual TD Cowen Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
14/02/202515:01Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
13/02/202519:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
13/02/202518:30Business WireVistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
06/02/202510:30Business WireVistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025NASDAQ:VTGNVistagen Therapeutics Inc
05/02/202510:30Business WireVistagen Receives U.S. Patent for AV-101 to Treat Neuropathic PainNASDAQ:VTGNVistagen Therapeutics Inc
14/01/202510:30Business WireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer CachexiaNASDAQ:VTGNVistagen Therapeutics Inc
13/01/202519:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
10/01/202510:30Business WireVistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
14/11/202418:19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/11/202410:30Business WireVistagen to Present at the Stifel 2024 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/11/202418:20Business WireVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
05/11/202410:30Business WireVistagen to Present at the 2024 Neuroscience Education Institute CongressNASDAQ:VTGNVistagen Therapeutics Inc
01/11/202409:30Business WireVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024NASDAQ:VTGNVistagen Therapeutics Inc
09/10/202409:30Business WireVistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health DayNASDAQ:VTGNVistagen Therapeutics Inc
23/09/202409:30Business WireVistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
13/08/202417:21Business WireVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
06/08/202409:30Business WireVistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
09/07/202409:30Business WireVistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of MigraineNASDAQ:VTGNVistagen Therapeutics Inc
27/06/202409:30Business WireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive YearNASDAQ:VTGNVistagen Therapeutics Inc
11/06/202417:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VTGNVistagen Therapeutics Inc
11/06/202417:20Business WireVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
11/06/202408:07IH Market NewsU.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices DeclineNASDAQ:VTGNVistagen Therapeutics Inc
07/06/202409:30Business WireVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024NASDAQ:VTGNVistagen Therapeutics Inc
29/05/202409:30Business WireVistagen to Present at the Jefferies Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
23/05/202409:30Business WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/05/202409:30Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
25/04/202409:30Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VTGN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios